CHICAGO — In this video, Sandra Mazzoni, DO, discusses the use of minimal residual disease, or MRD, testing in multiple myeloma. “There’s a lot of hot topics right now in myeloma in general,” Mazzoni, ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute ...

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics. Testing for minimal residual disease ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity. Measurable residual disease (MRD ...

MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...